74 results about "Non surgical treatment" patented technology

A system for surgical planning and therapeutic monitoring utilizes imaging data and computer-aided detection (CAD) technology to identify cancerous tumors. A pre-treatment report identifies all volumes of interest (VOIs) and provides data regarding the size and location of each VOI as well as volumetric data for use in surgical planning. The system can be used to monitor the progress of adjuvant chemotherapy or other non-surgical treatment and measures changes in tumor size and location. Post-treatment reports provide data regarding changes in tumor size and location as well as trend data to provide guidance to the physician.

Non-surgical treatments for idiopathic scoliosis include muscle stimulation therapy, chiropractic care, and the application of a variety of braces (orthotics). Surgical intervention frequently employs rigid metallic braces that prevent further flexing of the spine where applied. This invention allows flexing of the spine with long term correction of the scoliosis by application of small variable forces to supplant and counter the unbalance of the pertinent muscles. This invention may be applied to other spine problems in addition to idiopathic scoliosis as this invention permits and accommodates flexing of the spine and simultaneously supplies correcting and straightening forces.

In an embodiment, a method to enhance a non-surgical medical treatment, the method including applying a composition having an antifibrinolytic agent to an area of skin for non-surgical medical treatment, where the applying is at least one of before, during, and after the non-surgical medical treatment, beginning the non-surgical medical treatment to the area of skin, and continuing the non-surgical medical treatment until the non-surgical medical treatment is completed. In some embodiments, the antifibrinolytic agent is tranexamic acid in an amount of about 20% (w / v). In some embodiments, the method further includes minimizing, by the antifibrinolytic agent, bruising caused by the non-surgical medical treatment. In an additional embodiment, the present disclosure relates to a composition to enhance a non-surgical medical treatment, the composition having an antifibrinolytic agent. In a further embodiment, the present disclosure relates to a kit having a carrier and an antifibrinolytic agent.

The invention discloses a waist and abdomen (abdomen and waist) rehabilitation treatment machine. The waist and abdomen (abdomen and waist) rehabilitation treatment machine comprises a rack, wherein a hip and lower limb bracket for the part below the human sacroiliac joint and a head, chest and abdomen bracket for the part above the human pelvis are arranged on the rack along the longitudinal direction, and the waist and abdomen (abdomen and waist) rehabilitation treatment machine also comprises a human back work bracket which is arranged on the rack and positioned above the head, chest and abdomen bracket. The waist and abdomen (abdomen and waist) rehabilitation treatment machine has the advantages that on the basis of the clinical diagnosis and treatment practice of the department of orthopaedics of the traditional Chinese medicine and the western medicine, and through the observation and diagnosis and treatment study on the waist and abdomen (abdomen and waist) syndrome, the movements needed by functional recovery of the waist and abdomen (abdomen and waist) syndrome, namely, the application means needed by the all-side physiological function recovery, such as the massage to the abdomen, the dorsal stretch and traction to the body, the pull-press, push-movement, push pressing, lateral pull and lateral rotation for the waist, the traction shaking of the ankle, the body muscle loosing and the unique elastic impact and buffer massage for the waist and the back are scientifically applied to the functional rehabilitation treatment of the waist and the abdomen (abdomen and waist) through the mechanical working manner, and thus an effective rehabilitation treatment device is provided for the non-surgical treatment for the waist and abdomen (abdomen and waist) diseases.

Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

The invention discloses a lower lumbar segment unbalance rehabilitation therapeutic machine which comprises an upper working area supporting plate frame and a lower working area supporting plate frame, wherein the upper working area supporting plate frame is longitudinally arranged on a rack and is used for a region above a human hip joint; the lower working area supporting plate frame is arranged on the rack and is used for a region below the human hip joint; a headrest shoulder chest back backrest, a lumbar segment supporting device and a pelvis fixing device are longitudinally arranged on the upper working area supporting plate frame; a lower limb movement supporting device and an ankle elastic vibrating traction apparatus are longitudinally arranged on the lower working area supporting plate frame. The lower lumbar segment unbalance rehabilitation therapeutic machine has the advantages that the lower lumbar segment unbalance rehabilitation therapeutic machine is obtained based on traditional Chinese and western medicine orthopaedic clinical diagnosis and treatment practices; work doing treatment is carried out by taking the pelvis of a human body as a center point; the lower lumbar segment unbalance rehabilitation therapeutic machine takes in numerous application rehabilitation therapeutic technique modes such as pulling pressing, thrusting, jacking pressing, side-pulling side-rotation, traction vibration, stepped vibrating resetting, ankle traction trunk tendon loosening and the like of auxiliary application; the rehabilitation therapeutic equipment adopting a non-surgical treatment means is provided for patients who suffer from the lower lumbar segment unbalance disease.

Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

The invention discloses a Chinese medicinal preparation for treating urethritis, which is mainly prepared from medlar, Indian buead, common bombax flower, berry-bearing ammania, plantain seed, parslane herb, juncus effusus linne, dried persimmon, spreading hedyotis herb, common lophatherum herb, lightyellow sophora root, densefruit pttany root-bark, pink herb, rhizome dioscoreae hypoglaucae, grassleaf sweelflag rhizome, belvedere fruit, akebia stem, liquorice root, medicinal cyathula root and rice bean in a certain weight ratio. The Chinese medicinal preparation can be prepared into any common formulation for oral administration. The Chinese medicinal preparation treats the urethritis by adopting the means of the treatment of traditional Chinese medicines according to theory of traditional Chinese medical science and the principle of non-surgical treatment in western medicine, and has the advantages of definite curative effect and high cure rate.

The invention relates to the field of prevention and / or treatment of calcific aortic valvular disease. The inventors research and find that nobiletin can effectively down-regulate expression of osteogenic differentiation marker genes BMP2 and RUNX2 in valvular interstitial cells, and inhibit calcification of the valvular interstitial cells, thereby inhibiting or delaying valvular calcification, and further provide use of the nobiletin in preparing medicines for prevention and / or treatment of individual calcific aortic valvular disease. The invention provides a new option for non-surgical treatment of the calcific aortic valvular disease.

The invention provides inhibitors of α-crystallin aggregation and methods of using α-crystallin aggregation inhibitors to, e.g., treat or prevent cataracts in a subject having or at risk of developing cataracts. The invention further provides high throughput methods of screening compounds for modulation of protein thermal stability, the method comprising contacting a protein with each of a plurality of test compounds; and (b) measuring the melting transition (Tm) of the protein in the presence of each of the plurality of test compounds, wherein a compound that decreases or increases the apparent Tm by at least 2 standard deviations is identified as a pharmacological protein chaperone.

The invention discloses an oral medicament for treating osteonecrosis of the femoral head, which is mainly prepared from the following materials according to a certain weight ratio: szechuan lovage rhizome, rhizoma corydalis, red flower, Chinese polyphaga, salvia miltiorrhiza, suberect spatholobus stem, Chinese angelica, white paeony root, astragalus, codonopsis pilosula, prepared tuber of multiflower knotweed, eucommia ulmoides oliver, himalayan teasel root, medicinal indianmulberry root, medicinal cyathula root, medlar, Chinese magnoliavine fruit, fortune's drynaria rhizome, largehead atractylodes rhizome, indian buead, heracleum, Chinese taxillus twig, papaya, fangji root, root of largeleaf gentian, obscured homalomena rhizome, erythrina indica lam, divaricate saposhnikovia root, cassia twig, prepared common monkshood mother root, prepared kusnezoff monkshood root, swordlike atractylodes rhizome, earthworm, tall gastrodia tuber, oyster, oriental waterplantain rhizome, glabrous greenbrier rhizome and liquorice. The materials can be prepared into any common formulation for oral administration. The medicament for treating the osteonecrosis of the femoral head has the advantages of exact curative effect and high recovery rate by adopting treating means of traditional Chinese medicine according to the theory of traditional Chinese medicine and the non-surgical treatment principle of Western medicine.

The invention belongs to the technical field of medical apparatuses and instruments and rehabilitation engineering, and particularly relates to a multi-freedom-degree controllable lumbar vertebra treatment chair. The treatment chair comprises a rack mechanism, a chair mechanism, a transmission mechanism and a control device, wherein the control device is connected with the transmission mechanism through a connecting conductor bundle. The control device controls the transmission mechanism to drive the chair mechanism to carry out ascent, descent and multi-freedom-degree rotation on the rack mechanism, traction and appropriate motion of the specific parts of the lumbar vertebra of a treatment receiver are achieved, and the purpose of carrying out treatment on the lumbar vertebra of the patient with the lumbar vertebra disease is achieved. All types of motion of the treatment chair are controlled by preset programs in the control device to be completed, pilot run is carried out on a generated exercise therapy scheme before treatment is carried out, an operator holds an emergency shut-down button to ensure safety, and treatment can be started after the scheme is corrected. The treatment chair is reasonable in structure, easy to operate, applicable to non-surgical treatment of lumbar vertebra diseases, capable of effectively relieving and treating the disease parts, the course of treatment is shortened, and working difficulty and labor intensity of medical staff are reduced.

The invention provides an external Chinese medicinal composition capable of preventing the scarring healing of external injury. The external Chinese medicinal composition comprises 10 to 69 parts by weight of agrimonia pilosa ledeb, 10 to 50 parts by weight of raw rhizoma nelumbinis, 10 to 50 parts by weight of olibanum, 10 to 50 parts by weight of myrrh and 1 to 20 parts by weight of charred typha pollen. A preparation method comprises the following steps of weighing the cleaned and air-dried Chinese medicinal materials according to the formula; crushing the weighed Chinese medicinal materials for 10 to 15 minutes at the temperature of minus 220 to minus 50 DEG C under a sealed condition by using an ultralow-temperature or low-temperature crusher; causing the crushed Chinese medicinal materials to pass through a 300-mesh sieve, and collecting Chinese medicinal material powder; mixing the obtained Chinese medicinal material powder at the ratio in the formula, and performing sealing, packaging and storage. According to the external Chinese medicinal composition, different medicament ratios can be adopted, and the external Chinese medicinal composition can be used for the non-surgical treatment of different parts and people, livestock and poultry with different physiques for self-rescue or rescue by others; the external Chinese medicinal composition is easy to absorb and free of irritation and immunological rejection, and the aim of rapid skin physiological-healing without scarring can be fulfilled.

The invention discloses a pharmaceutical composition for treating leiomyoma of uterus and an application thereof and relates to the technical field of traditional Chinese medicines. The pharmaceutical composition comprises the following traditional Chinese medicinal materials in parts by weight: 35-42 parts of curcuma zedoary, 20-26 parts of leonurus, 18-25 parts of rhizoma sparganii, 18-25 parts of largehead atractylodes rhizome, 16-20 parts of Chinese angelica, 16-20 parts of root of bidentate achyranthes, 7-10 parts of liquorice and 5-8 parts of peach seed. The pharmaceutical composition disclosed by the invention can obviously improve symptom of myoma of uterus and inhibit growth of the myoma or eliminate the myoma, and can show the superiority of non-surgical treatment.

The invention relates to a slow-release implant agent of carmustine for tumor treatment, which is characterized in comprising effective amounts of carmustine, slow-release excipients and releasing regulatory agents in the slow-release implant agent. The excipients comprise macromolecules which are biologically compatible and degradable, mainly p (LAEG-EOP) and p (DAPG-EOP). The releasing regulatory agents are selected from one or more items from mannitol, sorbitol, xylitol, oligosaccharide, chitin, potassium salt, sodium salt, hyaluronic acid, collagen, chondroitin, gelatin and albumin. The slow-release implant agent slowly releases carmustine on the local tumor in the process of degradation and absorption, so the argent can evidently reduce the systemic toxicity and simultaneously apply to the effective drug concentration control on the local tumor. Therefore, the argent can be applied separately or combined with the non-surgical treatments such as chemotherapy drug and radiotherapy, which can be also widely used for tumor treatment of different phases, not only selectively improving the drug concentration on local tumor but also reinforcing the therapeutic effect of non-surgical treatments such as chemotherapy drug and radiotherapy.

The invention aims at providing a medical instrument which is applicable to light and intermediate obstructive sleep apnea-hypopnea syndromes and capable of relieving or eliminating the snore symptom. According to the medical instrument, the inadequacies of non-surgical treatment or surgical treatment of the obstructive sleep apnea-hypopnea syndrome are solved.

The invention relates to a slow-release implant agent of carmustine, which is characterized by effective amounts of carmustine, slow-release excipients and releasing regulatory agents in the slow-release implant agent. The excipients comprise macromolecules which are biologically compatible and degradable, mainly PLA and PLGA. The releasing regulatory agents are selected from one or more items from mannitol, sorbitol, xylitol, oligosaccharide, chitin, potassium salt, sodium salt, hyaluronic acid, collagen, chondroitin, gelatin and albumin. The slow-release implant agent slowly releases carmustine on the local tumor in the process of degradation and absorption, so the argent can evidently reduce the systemic toxicity and simultaneously apply to the effective drug concentration control on the local tumor. Therefore, the argent can be applied separately or combined with the non-surgical treatments such as chemotherapy drug and radiotherapy, which can be also widely used for tumor treatment of different phases, not only selectively improving the drug concentration on local tumor but also reinforcing the therapeutic effect of non-surgical treatments such as chemotherapy drug and radiotherapy.

The invention provides a medicine for treating liver cancer and a preparation method for the medicine. At present, clinical curative treatment methods for liver cancer comprise surgical treatment methods and non-surgical treatment methods. Lots of patients adopt surgical methods, and radiotherapy and chemotherapy treatment methods, which cause hair loss and relapse and further accelerate the time of death. The medicine for treating liver cancer comprises astragalus membranaceus, atractylodes macrocephala, radix codonopsitis, radix bupleuri, curcuma aromatica, corydalis tuber, honey-fried turtle shells, honey-fried pangolin scales, rhizoma sparganii, rhizoma curcumae, spreading hedyotis herb, lobelia, excrementum pteropi, raw cattail pollen, radix salviae miltiorrhizae, safflower, peach kernels, Szechuan lovage rhizome, honey-fried licorice and jujube. The medicine has a better curative effect on liver cancer.

The invention relates to the field of medical devices, in particular to a non-surgical treatment system for cervical decompression.The non-surgical treatment system comprises a pressure decompression bed, a pressure decompression control cabinet and a pressure decompression sliding assembly. The middle part of the pressure decompression bed is hinged onto a bed frame and can overturn to the bottom end of the pressure decompression bed. The pressure decompression sliding assembly comprises a headrest bottom plate and a fixing plate. One end of the headrest bottom plate is provided with a pressure decompression assembly. The pressure decompression assembly is connected with the pressure decompression control cabinet through a pressure decompression belt. The headrest bottom plate is movably connected with the fixing plate. One end of the fixing plate is hinged onto the front end of the decompression bed. A headrest is fixed on the headrest bottom plate. The upper surface of the headrest is provided with a groove matching the shape of an afterbrain of a human body. One side of the neck of the headrest is provided with two separable and fixed astoid bone rubber support blocks which are correspondingly fixed below the two mastoid bones. The two mastoid bone support blocks draw close to the part of the inner side and are in the conical shapes. The vertex of a taper points to the mastoid bone part of each headrest and the vertex of a taper is a fillet.

The present invention refers to a method for the non-surgical treatment of a lypodistrophy caused by an antiretroviral therapy in an individual infected by a retrovirus, such as HIV, and undergoing said antiretroviral therapy said method comprising the step of administering an effective amount of a adipocitolytic composition comprising deoxycholic acid and / or a pharmaceutically acceptable salt thereof in a retrovirus-infected individual affected by said lipodistrophy.

The invention relates to a slow-release implant agent of nimustine, which is characterized in comprising amounts of nimustine, slow-release excipients and releasing regulatory agents in the slow-release implant agent. The excipients comprise macromolecules which are biologically compatible and degradable, mainly PLA and PLGA. The releasing regulatory agents are selected from one or more items from mannitol, sorbitol, xylitol, oligosaccharide, chitin, potassium salt, sodium salt, hyaluronic acid, collagen, chondroitin, gelatin and albumin. The slow-release implant agent slowly releases nimustine on the local tumor in the process of degradation and absorption, so the argent can evidently reduce the systemic toxicity and simultaneously apply to the effective drug concentration control on the local tumor. Therefore, the argent can be applied separately or combined with the non-surgical treatments such as chemotherapy drug and radiotherapy, which can also be widely used for tumor treatment of different phases, not only selectively improving the drug concentration on local tumor but also reinforcing the therapeutic effect of non-surgical treatments such as chemotherapy drug and radiotherapy.

The current invention concerns a kit suitable for the non-surgical treatment of skin lesions including warts, verrucae, corns, and skin tags said kit comprising a cryogenic body comprising a housing hosting a coolant container and further comprising a cryogenic applicator head, whereby the housing and the cryogenic applicator head extend axially; said cryogenic applicator head is provided with a cryogenic tip for performing a cryogenic treatment to a skin lesion, whereby said coolant container contains a coolant suitable for cooling said tip; the kit further comprises an acid body comprising an acid container containing an acidic composition and having an acid outlet, and an acid dispenser head that axially extends from said acid container, is in fluid communication with said acid outlet, and is suitable for applying a dose of said acidic composition to a skin lesion. The invention also concerns a dosage regimen.

The invention provides a preparation method of a biological matrix gel material for promoting regeneration and repair of cartilage, a gel performance determination method and application. The steps include: adding a GP solution into a mixed solution of a human amniotic membrane-PEI system and a mixed solution of a chitosan solution to conduct blending treatment to obtain a chitosan / human amniotic membrane-PEI / GP system mixed solution with the biological matrix gel material as the matrix. The gel formed by the chitosan solution and the GP solution maintains the activity of cells in the mixed solution of the human amniotic membrane-PEI system, promotes the regeneration and repair of cartilage, and artificial joint replacement is no longer carried out for treatment, therefore, the non-surgical treatment effect of severe osteoarthritis formed by further development of cartilage injury is improved.

The device includes a wedge piece constructed for use in the non-surgical treatment of interproximal dental caries. A plunger is provided for driving substances through a passage in or on the wedge piece for enabling the delivery, to the site a carious lesion, of SDF or another substance that is effective for directly or indirectly killing, or biologically damaging, carious bacteria.

The invention belongs to the technical field of medical instrument structures, and particularly discloses a nickel-titanium alloy stent for treating megacolon. The stent is integrally bent into a longitudinal rainbow ring structure in a spiral spring shape or a ring shape from a transverse nickel-titanium alloy in a wave shape, the stent comprises a near-end expansion section and a far-end rectumend, and the diameter of the near-end expansion section is 10-15 mm larger than that of the far-end rectum end. The invention provides the nickel-titanium alloy stent for treating megacolon, the stentis placed at a lesion intestinal segment to expand an intestinal canal, so that intestinal contents smoothly pass through the narrow intestinal canal to be discharged out of the body, and the purposeof non-surgical treatment of the megacolon is achieved. The nickel-titanium alloy stent is used for treating the megacolon, surgical excision of the lesion intestinal canal is not needed, and variousinjuries and complications caused by surgeries are avoided.